| Dr Jill Bergeson Barkdull, MD | |
|
830 N 2000 W, Pleasant Grove, UT 84062-4047 | |
| (801) 756-1705 | |
| (801) 443-1164 |
| Full Name | Dr Jill Bergeson Barkdull |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 830 N 2000 W, Pleasant Grove, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043466899 | NPI | - | NPPES |
| 171564 | Other | UT | PEHP |
| 870293878 | Other | UT | EMI HEALTH |
| 107107195101 | Other | UT | SELECT HEALTH |
| 1043466899 | Other | UT | ALTIUS |
| 1043466899 | Other | UT | TRICARE |
| 1043466899 | Medicaid | UT | |
| 1126140 | Other | UT | DESERET HEALTHCARE TRUST |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 57647571205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Encompass Hospice Of Utah | Murray, UT | Hospice |
| Timpanogos Regional Hospital | Orem, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Family Medical | 7416197785 | 71 |
News Archive
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
VIGILAIR Systems, an industry leader in Ultraviolet Germicidal Irradiation technology was instrumental in a newly published, and first of its kind hospital study that demonstrated a dramatic reduction in patient Hospital Acquired Infections with the application of VIGILAIR® air cleaning technology in a Neonatal Intensive Care Unit.
Urinary tract infections account for nearly 40 percent of hospital-acquired infections in acute care hospitals, triggering increased hospital costs and higher patient morbidity and mortality rates. Compounding the toll of these infections, Medicaid, Medicare and many other payers no longer reimburse costs related to treatment because of their presumed preventability.
› Verified 9 days ago
| Entity Name | Premier Family Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750725735 PECOS PAC ID: 7416197785 Enrollment ID: O20130710000079 |
News Archive
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
VIGILAIR Systems, an industry leader in Ultraviolet Germicidal Irradiation technology was instrumental in a newly published, and first of its kind hospital study that demonstrated a dramatic reduction in patient Hospital Acquired Infections with the application of VIGILAIR® air cleaning technology in a Neonatal Intensive Care Unit.
Urinary tract infections account for nearly 40 percent of hospital-acquired infections in acute care hospitals, triggering increased hospital costs and higher patient morbidity and mortality rates. Compounding the toll of these infections, Medicaid, Medicare and many other payers no longer reimburse costs related to treatment because of their presumed preventability.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jill Bergeson Barkdull, MD 830 N 2000 W, Pleasant Grove, UT 84062-4047 Ph: (801) 756-3511 | Dr Jill Bergeson Barkdull, MD 830 N 2000 W, Pleasant Grove, UT 84062-4047 Ph: (801) 756-1705 |
News Archive
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
VIGILAIR Systems, an industry leader in Ultraviolet Germicidal Irradiation technology was instrumental in a newly published, and first of its kind hospital study that demonstrated a dramatic reduction in patient Hospital Acquired Infections with the application of VIGILAIR® air cleaning technology in a Neonatal Intensive Care Unit.
Urinary tract infections account for nearly 40 percent of hospital-acquired infections in acute care hospitals, triggering increased hospital costs and higher patient morbidity and mortality rates. Compounding the toll of these infections, Medicaid, Medicare and many other payers no longer reimburse costs related to treatment because of their presumed preventability.
› Verified 9 days ago
Marshall F Willis, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-756-1705 | |
Dr. Sean Cameron Doyle, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-443-1164 | |
Dr. Brannick Barton Riggs, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 360 S 1300 W, Pleasant Grove, UT 84062 Phone: 385-440-1400 Fax: 801-845-9965 | |
Scott L Smith, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-443-1164 | |
Elwood J Corry Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-443-1164 | |
Dr. Roger D. Brockbank, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-443-1164 |